Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar
Author | Abu-Raddad, Laith J. |
Author | Chemaitelly, Hiam |
Author | Ayoub, Houssein H. |
Author | Yassine, Hadi M. |
Author | Abdul Rahim, Hanan F. |
Author | Nasrallah, Gheyath K. |
Author | Benslimane, Fatiha M. |
Author | Al Khatib, Hebah A. |
Author | Al Khal, Abdullatif |
Author | Coyle, Peter |
Author | Al Kuwari, Einas |
Author | Butt, Adeel A. |
Author | Kaleeckal, Anvar H. |
Author | Shaik, Riyazuddin M. |
Author | Al Kanaani, Zaina |
Author | Latif, Ali Nizar |
Author | Jeremijenko, Andrew |
Author | Tang, Patrick |
Author | Hasan, Mohammad R. |
Author | Al Kuwari, Mohamed Ghaith |
Author | Bertollini, Roberto |
Author | Al Romaihi, Hamad Eid |
Author | Al Thani, Mohamed H. |
Author | The National Study Group for COVID-19 Vaccination |
Available date | 2023-12-28T05:14:43Z |
Publication Date | 2022 |
Publication Name | New England Journal of Medicine |
Resource | Scopus |
ISSN | 284793 |
Abstract | In early 2021, Qatar launched a mass immunization campaign with the mRNA-1273 (Moderna)1 vaccine against coronavirus disease 2019 (Covid-19).2 We assessed the persistence of real-world vaccine effectiveness against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and against Covid-19-related hospitalization and death.We used a test-negative, case-control study design to estimate vaccine effectiveness, applying the same methods used recently to assess waning effectiveness of the BNT162b2 (Pfizer-BioNTech) vaccine in the same population.3 Case participants (persons with a positive polymerase-chain-reaction [PCR] test for SARS-CoV-2) and controls (PCR-negative persons) were matched one to one according to sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test. Effectiveness was estimated against documented infection (a PCR-positive swab, regardless of the presence of symptoms) and against any severe Covid-19 cases (acute-care hospitalizations), critical Covid-19 cases (intensive care unit hospitalizations), or fatal Covid-19 cases (Covid-19-related deaths). |
Sponsor | The study described in this letter was supported by grants from the National Institutes of Health (NIH) (75N93019C00050, to Drs. Montefiori and Shen; U19 AI142790, to Dr. Korber; and UM1 AI148689, to Dr. Lyke), Moderna, and the Intramural Research Program of the Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), NIH. The Duke and Vaccine Research Center laboratories received funding for sample analysis from Moderna. The Coronavirus Efficacy (COVE) trial (ClinicalTrials.gov number, NCT04470427) was supported by the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA) (contract number, 75A50120C00034) and by the NIAID. The NIAID provides grant funding to the HIV Vaccine Trials Network (HVTN) Leadership and Operations Center (UM1 AI 68614HVTN), the Statistics and Data Management Center (UM1 AI 68635), the HVTN Laboratory Center (UM1 AI 68618), the HIV Prevention Trials Network Leadership and Operations Center (UM1 AI 68619), the AIDS Clinical Trials Group Leadership and Operations Center (UM1 AI 68636), and the Infectious Diseases Clinical Research Consortium leadership group 5 (UM1 AI148684-03). Parts A and B of the phase 2 trial (Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older; NCT04405076) were supported by federal funds from the Office of the Assistant Secretary for Preparedness and Response, BARDA (contract number, 75A50120C00034) and Moderna. The phase 2-3 trial (A Study to Evaluate the Immunogenicity and Safety of mRNA-1273.211 Vaccine for COVID-19 Variants; NCT04927065) was supported by Moderna. |
Language | en |
Publisher | Massachussetts Medical Society |
Subject | mRNA-1273 Vaccine SARS-CoV-2 Covid-19 Moderna vaccine |
Type | Other |
Pagination | 1091-1093 |
Issue Number | 11 |
Volume Number | 386 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |
This item appears in the following Collection(s)
-
Biomedical Sciences [711 items ]
-
COVID-19 Research [811 items ]